Clover posts positive phase‑2 data

Clover Biopharmaceuticals said on September 6 that its phase-2 readout in Australia kept two questions in focus at once: whether its combination respiratory vaccines work in older adults, and whether they can still be used in people who already got one of the first approved RSV shots. The company reported positive preliminary data for SCB-1022, which targets RSV and human metapneumovirus, and SCB-1033, which adds parainfluenza virus type 3. Clover said both candidates produced robust neutralizing antibody responses in adults ages 60 to 85, with a favorable safety and tolerability profile. (morningstar.com) That matters because the RSV market is no longer empty. GSK’s Arexvy, Pfizer’s Abrysvo and Moderna’s mRESVIA are already approved RSV vaccines, and Clover is explicitly framing its candidates around revaccination and broader pathogen coverage rather than a simple first-shot launch. ### Why is Clover talking so much about revaccination? (morningstar.com) Clover Chief Executive Joshua Liang said the company sees “the potential differentiated ability to re-vaccinate individuals previously receiving approved RSV vaccines to restore and broaden protection.” That language has been central to Clover’s RSV program since earlier phase-1 updates and remained the lead commercial message in the phase-2 release. (clinicaltrialvanguard.com) Approved RSV vaccines created a new problem for late entrants: many older adults have already been immunized against RSV alone. Clover’s pitch is that a follow-on shot covering RSV plus hMPV, with or without PIV3, could offer a reason to vaccinate again rather than compete only for unvaccinated patients. That framing was described in the company’s release and echoed in follow-up coverage of the data. (morningstar.com) ### What did the phase-2 study actually test? The phase-2 trial enrolled 420 older adults ages 60 to 85 in Australia in a randomized, observer-blinded, multi-center study. Participants were assigned to receive SCB-1022, SCB-1033 or placebo. At 28 days after vaccination, Clover said the two-pathogen and three-pathogen candidates generated strong neutralizing antibody increases against RSV and hMPV, while SCB-1033 also produced responses against PIV3. (morningstar.com) The company said adding PIV3 did not reduce the RSV or hMPV immune response, a result it described as showing no immune interference. Adults 75 and older were another focus. Clover said responses in that subgroup did not drop off versus participants ages 60 to 74, which is a notable detail in a vaccine study aimed at older patients. ### Why include hMPV and PIV3 at all? Human metapneumovirus and parainfluenza virus type 3 are respiratory viruses that can also cause serious disease in older adults, but there are no broadly used approved vaccines for those pathogens in this population. (clinicaltrialvanguard.com) Clover’s candidates are designed as combination shots, using its prefusion-stabilized F protein antigens and Trimer-Tag platform. (morningstar.com) The commercial logic is straightforward in the company’s own materials: broader coverage could help distinguish the product in a market where RSV-only vaccination is already established. Clover has also pointed investors to Sanofi’s July 2025 acquisition of Vicebio as evidence of industry interest in RSV+hMPV combinations. ### How far along is the program now? January 2026 was when Clover said it had started the phase-2 study in Australia after earlier phase-1 data. (morningstar.com) The September 6 update said the positive preliminary results, together with successful 2,000-liter commercial-scale production, further reduced development and commercialization risk ahead of later-stage work. Clover said full phase-2 data will be presented at a future scientific meeting. (cloverbiopharma.com) The next concrete markers are those detailed results and the company’s plans for late-stage development of SCB-1022 and SCB-1033. (morningstar.com) (cloverbiopharma.com)